Trial Profile

A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 07 Apr 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sarecycline (Primary)
Indications Acne vulgaris
Focus Adverse reactions; Registrational
Sponsors Actavis; Almirall S.A.

Most Recent Events

06 Dec 2019 According to an Almirall S.A. Media Release, company announced publication of data from this trial.
06 Dec 2019 According to an Almirall S.A. Media Release, David M. Pariser, MD, FACP, FAAD of the Virginia Clinical Research Center in Norfolk, Virginia and principal investigator for the study.
06 Dec 2019 Results presented in an Almirall S.A. Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com